In vivo Grade Recombinant Anti-mouse CD28 Monoclonal Antibody, Syrian Hamster IgG2 (Clone: 37.51) PA007475.hs2 Syd Labs

Anti-mouse CD28 Monoclonal Antibody (Clone: 37.51) | PA007475.hs2

Name: Anti-mouse CD28 Monoclonal Antibody (Clone: 37.51) | Ushelf
Brand: Syd Labs
SKU: PA007475.hs2
Price: 150-900 USD
Availability: InStock
Rating: 5 (1 reviews)

$150.00 – $900.00

Recombinant Hamster IgG2 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

Details & Specifications
References

Catalog No.	PA007475.hs2
Product Name	In vivo Grade Recombinant Anti-mouse CD28 Monoclonal Antibody, Syrian Hamster IgG2 (Clone: 37.51)
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	T-cell-specific surface glycoprotein CD28; TP44
Clone	37.51
Isotype	Syrian Hamster IgG2.
Source/Host	The anti-mouse CD28 monoclonal antibody (clone: 37.51) was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade recombinant hamster monoclonal antibody (clone: 37.51) specifically binds to the mouse CD28 protein.
Applications	ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD28 protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The In vivo Grade Recombinant Anti-mouse CD28 Monoclonal Antibody, Syrian Hamster IgG2 (Clone: 37.51) is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant Hamster IgG2 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007475.hs2: Recombinant Anti-mouse CD28 Monoclonal Antibody(Clone: 37.51), Syrian Hamster IgG2, In vivo Grade

Recombinant Syrian Hamster IgG2 Monoclonal Antibody.

References of Anti-Mouse CD28 Monoclonal Antibody

1. Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction
Rouhani, S. J., et al. Nat Commun. 2015 Apr 10;6:6771. doi: 10.1038/ncomms7771. PMID: 25857745
“However, Bg2 cells adoptively transferred into MHC-II-/-Prox1x-gal chimeras treated with ?CD28 agonistic antibodies also did not proliferate. …CTV-labelled Bg2 cells were adoptively transferred into B6 and MHC-II-/-Prox1x-gal mice treated with PBS, ?CD28 or IFN-?, and proliferation was analysed 3 days later. Plots are gated on Thy1.1+CD4+ cells. Data representative of 2 experiments with 2 mice each. …CD4 co-cultures also received 0.25??g?ml?-1 ?CD28 (clone 37.51). …Mice were irradiated (6.5?Gy × 2) and reconstituted with a minimum of 2 × 10^6 bone marrow cells depleted of CD4+ and CD8+ T cells (Miltenyi Biotec) to prevent graft-versus-host disease. …Single colour images of LAMP1 and cathepsin L staining were imported into ImageJ and thresholded to identify positive vesicles as greater than 10 pixels in area.”

2. Multiple layers of CD80/86-dependent costimulatory activity regulate primary, memory, and secondary lymphocytic choriomeningitis virus-specific T cell immunity
Eberlein, J., et al. J Virol. 2012 Feb;86(4):1955-70. doi: 10.1128/JVI.05949-11. PMID: 22156513
“A case in point is the costimulatory triad of CD28, CD80 (B7.1), and CD86 (B7.2), the role of which has been explored in numerous experimental settings. …To date, infections with multiple distinct and related viruses, escalating dosages, and various challenge routes have been employed to ascertain the role of CD28-CD80/86 costimulation preferentially in CD28-/- mice but also complemented by analyses of CD80-/- and/or CD86-/- strains as well as ligand (anti-CD80/86 and CTLA-4Ig) and receptor (anti-CD28 and anti-CTLA-4) blockade. …For the third paradigm, as reviewed previously by Boesteanu and Katsikis (9), the development of the concept that secondary TE responses are less dependent on CD28-CD80/86 costimulation than primary TE responses was based in large part on in vitro experiments. …Although a similar interpretation was proposed for some nonviral model systems (50), this observation is also compatible with the notion of an activating CD80/86 receptor other than CTLA-4 or CD28. …It should be noted that the impaired proliferative expansion of CD28-/- secondary CD8+ TE was also observed in experiments in which wt and CD28-/- CD8+ TM were transferred into separate recipients (not shown), thus ruling out a competitive disadvantage of CD28-/- T cells in the combined AT/rechallenge experiments described above.”